NCT05278962CompletedPhase 4
HF Patients With LVADs Being Treated With SGLT2i
Heart Failure Patients With Left Ventricular Assist Devices Being Treated With Sodium-Glucose Co-Transporter 2 Inhibitors
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 4 Mar 2022
- Start date
- 8 Sept 2022
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- University of Chicago
- Diseases
- Heart failure
- NCT number
- NCT05278962
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 32
- From 8 Sept 2022 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of Type 1 diabetes mellitus
Lab values
- eGFR \< 30 ml/min/1.73 m2
Age
- Age \< 18 years-old
Who the study is looking for
- LVAD implantation
- Have not already been prescribed management with an SGLT2i
- Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2
- Age ≥ 18 years-old
- Able to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.